Starpharma Holdings Limited (ASX:SPL) Filings

Starpharma Holdings Limited

Filings

FilingDateTypeFiled with
Chair and Deputy Chair AppointmentsNov 5, 2026Management or board changeASX
Results of 2026 Annual General MeetingNov 5, 2026Meeting outcomeASX
AGM Chair address and CEO presentationNov 5, 2026Meeting outcomeASX
Becoming a substantial holderNov 2, 2026Ownership change noticeASX
Application for quotation of securities - SPLOct 29, 2026FinancingASX
Details of Company AddressOct 23, 2026Other filingsASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 21, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 21, 2026Quarterly reportASX
$3.5 Million R&D Tax Incentive ReceivedOct 21, 2026Other filingsASX
Starpharma Investor Presentation Petalion WebinarOct 20, 2026Operations updateASX
Starpharma secures majority ownership of PetalionOct 19, 2026Acquisition or disposalASX
Starpharma secures majority ownership of PetalionOct 19, 2026Acquisition or disposalASX
Trading HaltOct 15, 2026Trading halt or suspensionASX
Change in substantial holdingOct 7, 2026Ownership change noticeASX
Notice of Annual General Meeting/Proxy FormOct 5, 2026Meeting noticeASX
Change of Director's Interest Notice - C MaleyOct 4, 2026Ownership change noticeASX
Application for quotation of securities - SPLOct 4, 2026FinancingASX
Notification of cessation of securities - SPLOct 4, 2026FinancingASX
Chair and Deputy Chair AppointmentsSep 30, 2026Management or board changeASX
Ceasing to be a substantial holderSep 25, 2026Ownership change noticeASX
Becoming a substantial holderSep 22, 2026Ownership change noticeASX
Ceasing to be a substantial holderSep 15, 2026Ownership change noticeASX
Annual General Meeting 2026 DateSep 15, 2026Meeting noticeASX
Becoming a substantial holderSep 11, 2026Ownership change noticeASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
Ceasing to be a substantial holderAug 31, 2026Ownership change noticeASX
FY26 Key Financial Results and Annual ReportAug 25, 2026Annual reportASX
2026 Appendix 4G and Corporate Governance StatementAug 25, 2026Other filingsASX
2026 Annual ReportAug 25, 2026Annual reportASX
Preliminary Final ReportAug 25, 2026ResultsASX
Becoming a substantial holderAug 24, 2026Ownership change noticeASX
Ceasing to be a substantial holderAug 19, 2026Ownership change noticeASX
Change in substantial holdingAug 18, 2026Ownership change noticeASX
Change in substantial holdingAug 13, 2026Ownership change noticeASX
Change of Director Interest Notice - R BasserAug 12, 2026Management or board changeASX
Change of Director Interest Notice - R ThomasAug 12, 2026Management or board changeASX
Change of Director Interest Notice - L ChengAug 12, 2026Management or board changeASX
Change of Director Interest Notice - J DaviesAug 12, 2026Management or board changeASX
Change of Director Interest Notice - C MaleyAug 12, 2026Management or board changeASX
Becoming a substantial holderAug 11, 2026Ownership change noticeASX
Successful Completion of $32 million Entitlement OfferAug 10, 2026FinancingASX
Application for quotation of securities - SPLAug 10, 2026FinancingASX
Entitlement Offer Investor PresentationJul 14, 2026Offer documentASX
Fully Underwritten Entitlement Offer to Raise $32 MillionJul 14, 2026FinancingASX
Quarterly Activities Report and Appendix 4CJul 14, 2026Quarterly reportASX
DEP milestone triggers partner option feeJul 2, 2026Operations updateASX
Positive DEP HER2-Lu preclinical data support Phase 1 entryJul 1, 2026Other filingsASX
DEP radiopharmaceutical data supports patent applicationJul 1, 2026Other filingsASX
FDA confirms path to DEP HER2 first-in-human studyApr 21, 2026Other filingsASX
Half Yearly Report and AccountsFeb 17, 2026Interim reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 28, 2026Quarterly reportASX
AGM Chair address and CEO presentationNov 14, 2025Meeting outcomeASX
Upfront payment of USD $5.5 million received from GenentechOct 21, 2025Acquisition or disposalASX
SPL:Research & Option Agreement with Radiopharm TheranosticsSep 30, 2025Other filingsASX
Presentation to Accompany License Agreement with GenentechSep 21, 2025Operations updateASX
Starpharma Announces License Agreement with GenentechSep 21, 2025Material contractASX
$3.7M R&D Tax Incentive ReceivedAug 27, 2025ResultsASX
FY25 Key Financial Results and Annual ReportAug 26, 2025Annual reportASX
2025 Appendix 4E Preliminary Financial ReportAug 26, 2025ResultsASX
SPL receives positive FDA feedback on DEP SN38 for PROCDec 18, 2024Other filingsASX
AGM Chair's address and CEO's presentationNov 26, 2024Meeting outcomeASX
SPL7013 Nasal Spray Australia UpdateOct 17, 2024Other filingsASX
Starpharma Receives $5.5M R&D Tax Incentive RefundSep 11, 2024Other filingsASX
Annual Report to shareholdersAug 21, 2024Annual reportASX
Positive final DEP irinotecan Phase 2 clinical trial resultsMay 27, 2024Other filingsASX
Starpharma Business UpdateMay 22, 2024Operations updateASX
Starpharma and Medicxi Partnership Petalion TherapeuticsApr 7, 2024Acquisition or disposalASX
S&P DJI Announces March 2024 Quarterly RebalanceMar 1, 2024Other filingsASX
VivaGel BV US FDA Appeal OutcomeFeb 18, 2024Legal or regulatory actionASX
Viraleze shows antiviral efficacy in COVID-19 patientsJan 28, 2024ResultsASX
VivaGel BV sales and distribution agreement MENA regionJan 22, 2024Operations updateASX
Positive DEP docetaxel Phase 2 resultsDec 18, 2023ResultsASX
AGM Chairman's address and CEO presentationNov 29, 2023Other filingsASX
Starpharma announces new CEO, Ms Cheryl MaleyNov 9, 2023Management or board changeASX
Starpharma receives $7.2 million R&D Tax Incentive refundOct 22, 2023ResultsASX
Positive DEP Cabazitaxel Phase 2 Results in Multiple CancerOct 17, 2023ResultsASX
DEP irinotecan clinical data presented at AACR meetingOct 15, 2023Operations updateASX
DEP irinotecan combination data presentationSep 26, 2023Operations updateASX
VIRALEZ UK COVID-19 Clinical Study Completes RecruitmentSep 25, 2023Operations updateASX
Positive DEP irinotecan clinical results presentationSep 13, 2023Other filingsASX
App 4E/Annual Report to shareholdersAug 23, 2023Annual reportASX
SPL to receive $6.5M from Mundipharma and VivaGel BV rightsAug 13, 2023Other filingsASX
Partnered Program UpdateJul 31, 2023Other filingsASX
Trading HaltJul 28, 2023Trading halt or suspensionASX
Pause in TradingJul 28, 2023Trading halt or suspensionASX
Starpharma partners with UQ to advance DEP radio pipelineJul 25, 2023Other filingsASX
DEP HER2-radiodiagnostic shows imaging benefitsJul 20, 2023Other filingsASX
Clinical Trial UpdateJun 27, 2023Other filingsASX
Starpharma CEO to retire in 2024Jun 8, 2023Other filingsASX
VIRALEZE Nasal Spray Approved in MalaysiaJun 5, 2023Other filingsASX
HER2-targeted DEP SN38 ADC outperforms in HER2 cancer modelApr 26, 2023Other filingsASX
Interim Report and Half-Year Financial ResultsFeb 27, 2023Interim reportASX
Quarterly Activities Report & Appendix 4CJan 29, 2023Quarterly reportASX
Response to ASX Query LettersJan 12, 2023Explanation requestASX
Starpharma receives $7.1M R&D tax incentive refundDec 22, 2022Other filingsASX
VIRALEZE Nasal Spray Registered in IndonesiaDec 14, 2022Other filingsASX
Positive AZD0466 clinical data presented by AstraZenecaDec 13, 2022Other filingsASX
AGM Chairman address and CEO presentationNov 29, 2022Other filingsASX
VIRALEZE distribution agreement for Hong Kong and MacauOct 20, 2022Other filingsASX
New clinical data for DEP cabazitaxel in prostate cancerSep 11, 2022Other filingsASX
S&P DJI Announces September 2022 Quarterly RebalanceSep 2, 2022Other filingsASX
Starpharma annual report and full year financial resultsAug 25, 2022Annual reportASX
Starpharma signs new DEP agreement with MSDAug 10, 2022Other filingsASX
VIRALEZE Protects Against Omicron in Viral Challenge ModelJul 20, 2022Other filingsASX
VIRALEZE relaunched by LloydsPharmacy in the UKJun 30, 2022Other filingsASX
SPL signs expanded DEP research agreement with US BiopharmaJun 26, 2022Other filingsASX
SPL7013 in VIRALEZE virucidal against influenza A and BMay 17, 2022Other filingsASX
Quarterly Cashflow and Activities ReportApr 29, 2022Quarterly reportASX
VIRALEZE to relaunch in the UKMar 31, 2022Other filingsASX
SPL7013 in VIRALEZE virucidal against OmicronMar 1, 2022Other filingsASX
VIRALEZE sales and distribution in Saudi Arabia and GCCFeb 2, 2022Other filingsASX
Starpharma receives $7.7M R&D tax incentive refundJan 19, 2022Other filingsASX
VIRALEZE successfully launched in VietnamDec 13, 2021Other filingsASX
Starpharma signs DEP Research Agreement with US Biopharma CoDec 6, 2021Other filingsASX
VIRALEZE distribution agreement and launch in VietnamDec 2, 2021Other filingsASX
VIRALEZE registered in Vietnam with launch this weekNov 30, 2021Other filingsASX
Positive DEP phase 2 interim results in prostate cancerNov 25, 2021Interim reportASX
VIRALEZE distribution and supply to VietnamOct 25, 2021Other filingsASX
VIRALEZE launch in ADMENTA Italia Group pharmacies in ItalyOct 7, 2021Other filingsASX
VIRALEZE Protects Against SARS-CoV-2 in Challenge ModelAug 23, 2021Other filingsASX
VIRALEZE well tolerated in multiple dose clinical studyAug 17, 2021Other filingsASX
VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variantJul 27, 2021Other filingsASX
VIRALEZE UK UpdateJun 20, 2021Other filingsASX
VIRALEZE SPL7013 virucidal against multiple COVID variantsJun 17, 2021Other filingsASX
VIRALEZE antiviral nasal spray registered for sale in IndiaJun 11, 2021Other filingsASX
VIRALEZE SPL7013 highly active in UK variant of coronavirusJun 1, 2021Other filingsASX
VIRALEZE launches in EuropeMay 6, 2021Other filingsASX
VIRALEZE to be launched with LloydsPharmacy in the UKMar 24, 2021Other filingsASX
DEP HER2-lutetium outperforms in human breast cancer modelMar 15, 2021Other filingsASX
VIRALEZE antiviral nasal spray registered in EuropeFeb 22, 2021Other filingsASX
Starpharma signs DEP ADC Research Agreement with MSDFeb 11, 2021Other filingsASX
AZD0466 clinical DEP program global expansionFeb 8, 2021Other filingsASX
VIRALEZE COVID-19 nasal spray study to commence in JanuaryDec 22, 2020Other filingsASX
VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21Dec 9, 2020Other filingsASX
SPL7013 shows potent antiviral activity in RSVNov 18, 2020Other filingsASX
Completion of Placement and SPP raises $48.9M in totalOct 29, 2020FinancingASX
Starpharma receives $5.7M R&D tax incentive refundOct 20, 2020Other filingsASX
Share Purchase Plan offer documentOct 6, 2020FinancingASX
Starpharma completes oversubscribed A$45M placementSep 30, 2020FinancingASX
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2Sep 14, 2020Other filingsASX
Starpharma awarded $1M MRFF funding for COVID-19 spraySep 2, 2020Other filingsASX
SPL creates slow release soluble DEP remdesivir nanoparticleAug 31, 2020Other filingsASX
SPL7013 nasal spray for COVID19 development updateAug 25, 2020Other filingsASX
Starpharma signs new DEP partnership with Chase SunAug 16, 2020Other filingsASX
DEP irinotecan boosts immuno-oncology in colon cancer modelsJun 28, 2020Other filingsASX
DEP products showcased at AACR 2020Jun 22, 2020Other filingsASX
DEP lutetium effective in human prostate cancer modelJun 17, 2020Other filingsASX
VivaGel BV launched in central and eastern EuropeJun 16, 2020Other filingsASX
DEP irinotecan phase 2 commences after positive phase 1May 7, 2020Other filingsASX
SPL7013 shows significant activity against coronavirusApr 15, 2020Other filingsASX
Quarterly Cashflow and Activity ReportApr 7, 2020Quarterly reportASX
Okamoto licenses VivaGel antiviral condom in Asian countriesMar 3, 2020Other filingsASX
VivaGel BV launched in AsiaFeb 12, 2020Other filingsASX
Starpharma receives US$3M milestone from AstraZenecaFeb 10, 2020Other filingsASX
Quarterly Cashflow ReportJan 28, 2020Quarterly reportASX
Commencement of phase 1 trial for AZD0466 utilising DEPDec 29, 2019Other filingsASX
Starpharma receives $4.9M R&D tax incentive refundDec 15, 2019Other filingsASX
DEP cabazitaxel progresses to phase 2 on positive resultsDec 9, 2019Other filingsASX
AGM - Chairman address and CEO presentationNov 21, 2019Other filingsASX
VivaGel condom receives regulatory approval in EuropeNov 20, 2019Other filingsASX
UK launch of VivaGel BVNov 12, 2019Other filingsASX
DEP outperforms Gemzar in human pancreatic cancer modelOct 30, 2019Other filingsASX
FDA Authorises Clinical Trial with AstraZeneca DEP productSep 25, 2019Other filingsASX
DEP irinotecan synergistic with Lynparza in refractory modelSep 12, 2019Other filingsASX
VivaGel BV regulatory approvals continue in AsiaSep 2, 2019Other filingsASX
Positive results with Targeted DEP using antibody fragmentAug 29, 2019Other filingsASX
Promising efficacy signals observed in ongoing DEP trialsAug 27, 2019Other filingsASX
First Asian Regulatory Approvals Received for VivaGel BVAug 14, 2019Other filingsASX
Starpharma commences phase 1/2 DEP irinotecan trialAug 7, 2019Other filingsASX
VivaGel BV launched in EuropeJun 27, 2019Other filingsASX
Starpharma signs second oncology agreement with AstraZenecaJun 2, 2019Other filingsASX
DEP irinotecan combination outperforms in colon cancel modelMay 24, 2019Other filingsASX
First VivaGel BV launch globally in Australia by AspenApr 16, 2019Other filingsASX
Starpharma receives $4.0M R&D tax incentive refundMar 11, 2019Other filingsASX
Interim Report and Half-Yearly Financial ResultsFeb 26, 2019Interim reportASX
Response to ASX Aware LetterJan 7, 2019Explanation requestASX
VivaGel condom receives final regulatory approval in JapanJan 1, 2019Other filingsASX
US FDA requests further data for VivaGel BV approvalDec 27, 2018Other filingsASX
US VivaGel BV licensed for A$142M milestones plus royaltiesDec 19, 2018Other filingsASX
DEP products outperform in human pancreatic cancer modelNov 16, 2018Other filingsASX
Starpharma Investor Presentation for Citi ConferenceOct 16, 2018Other filingsASX
DEP irinotecan outperforms in pancreatic cancer modelSep 5, 2018Other filingsASX
AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacyAug 31, 2018Other filingsASX
Annual report and full year financial resultsAug 21, 2018Annual reportASX
VivaGel BV NDA advances to next stage of FDA reviewJul 9, 2018Other filingsASX
Starpharma licenses VivaGel BV to Mundipharma for EuropeJun 26, 2018Other filingsASX
Mundipharma licenses Starpharmas VivaGel BVMay 3, 2018Other filingsASX
Appendix 4C - Quarterly Cashflow ReportApr 30, 2018Quarterly reportASX
Starpharma completes US New Drug Application for VivaGel BVApr 29, 2018Other filingsASX
Starpharma receives $3.7M R&D tax incentive refundFeb 21, 2018Other filingsASX
Starpharma to commence DEP cabazitaxel phase 1/2 trialJan 31, 2018Other filingsASX
VivaGel BV treatment clinical submission under rolling NDADec 20, 2017Other filingsASX
NDA submission for VivaGel BV in the USNov 21, 2017Other filingsASX
VivaGel BV granted marketing approval in AustraliaOct 24, 2017Other filingsASX
Starpharma and Peter Mac Cancer Centre awarded DEP GrantOct 9, 2017Other filingsASX
AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitorSep 28, 2017Other filingsASX
DEP docetaxel positive phase 1 results, phase 2 commencesSep 22, 2017Other filingsASX
Starpharma and Monash awarded STEM Business FellowshipsAug 9, 2017Other filingsASX
Successful VivaGel Phase 3 results and NDA planned for rBVAug 6, 2017Other filingsASX
VivaGel BV phase 3 results timing and commercialisationJul 4, 2017Other filingsASX

This page holds 200 of 298 filings.